Comments on: KALYDECO® ( ivacaftor ) Approved By FDA For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutation

Comments on: KALYDECO® ( ivacaftor ) Approved By FDA For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutation https://www.worldpharmatoday.com/news/kalydeco-ivacaftor-approved-by-fda-for-more-than-600-people-ages-2-and-older-with-cystic-fibrosis-who-have-certain-residual-function-mutation/ Magazine for the C-level Pharma Executives Tue, 01 Aug 2017 06:12:15 +0000 hourly 1 https://wordpress.org/?v=6.9.4